Your session is about to expire
← Back to Search
Unknown
A Bioavailability and Food Effect Study of AZD5462 in Healthy Volunteers
Phase 1
Waitlist Available
Research Sponsored by AstraZeneca
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1 to day 17
Awards & highlights
No Placebo-Only Group
Summary
This trial tests a new medication called AZD5462 in healthy men and women who cannot have children. Researchers want to see how the body absorbs, distributes, and processes the medication in both pill and liquid forms.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ day 1 to day 17
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1 to day 17
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Area under plasma concentration time curve from zero to infinity (AUCinf)
Area under the plasma concentration-curve from time zero to last quantifiable concentration (AUClast)
Maximum observed plasma (peak) drug concentration [Cmax]
Secondary study objectives
Number of participants with Adverse Events (AEs), and Serious Adverse Events (SAEs)
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
6Treatment groups
Experimental Treatment
Group I: Treatment FExperimental Treatment1 Intervention
Participants will receive Dose C orally as a film-coated tablet.
Group II: Treatment EExperimental Treatment1 Intervention
Participants will receive Dose C orally as a film-coated tablet.
Group III: Treatment DExperimental Treatment1 Intervention
Participants will receive Dose B orally as an oral solution.
Group IV: Treatment CExperimental Treatment1 Intervention
Participants will receive Dose B orally as a film-coated tablet.
Group V: Treatment BExperimental Treatment1 Intervention
Participants will receive Dose A orally as a film-coated tablet.
Group VI: Treatment AExperimental Treatment1 Intervention
Participants will receive Dose A orally as a film-coated tablet.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
AZD5462
2022
Completed Phase 1
~150
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
AstraZenecaLead Sponsor
4,411 Previous Clinical Trials
289,123,057 Total Patients Enrolled
ParexelIndustry Sponsor
313 Previous Clinical Trials
96,668 Total Patients Enrolled